Fred Alger Management, LLC Revance Therapeutics, Inc. Transaction History

Fred Alger Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$18.06 - $24.96 $541,800 - $748,800	-30,000 Closed	0 $0
Q2 2018 Jul 19, 2018	SELL	$27.45 - $33.35 $381,966 - $464,065	-13,915 Reduced 31.69%	30,000 $824,000
Q1 2018 May 10, 2018	BUY	$29.15 - $37.4 $551,372 - $707,421	18,915 Added 75.66%	43,915 $1.35 Million
Q4 2017 Feb 14, 2018	BUY	$24.55 - $36.3 $613,750 - $907,499	25,000	25,000 $894,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.